45 results
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
for conference calls with management and your Board of Directors or the Audit Committee of your Board of Directors. We will prepare a board package containing
424B5
INM
InMed Pharmaceuticals Inc
3 Jun 22
Prospectus supplement for primary offering
9:45pm
at the highest dose. 108 different central nervous system criteria were measured.
The toxicology and safety pharmacology data package covered
424B3
akv1pc8y
25 Apr 22
Prospectus supplement
5:02pm
8-K
EX-99.1
dob2iv9
21 Apr 22
Regulation FD Disclosure
2:46pm
424B3
ce0ynzzyzk52gcicw
7 Apr 22
Prospectus supplement
4:46pm
S-3
f2fbtzhccujnolczp
4 Feb 22
Shelf registration
4:36pm
8-K
EX-99.1
jf284wak tedrlx5
5 Jan 22
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2:22pm
DEF 14A
p056r
28 Oct 21
Definitive proxy
3:07pm
8-K
EX-2.1
s4x7mw144 pk1
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
10-K
EX-2.1
j41ws1nszqngoph1h
24 Sep 21
Annual report
7:31am
10-K
a9a9ssxwu zrcjjkap
24 Sep 21
Annual report
7:31am
424B3
2s2pco9 i2
22 Jul 21
Prospectus supplement
10:27am
8-K
EX-99.1
lnpada5cvq
28 Apr 21
Regulation FD Disclosure
11:43am
424B3
3f49yz29 n2hbumdwe
16 Mar 21
Prospectus supplement
12:00am